Business
Cellectar and Evestia Clinical Announce Partnership to Support Auger-Emitting Radiopharmaceutical Clinical Trial in Triple-Negative Breast Cancer (TNBC)
Intends to Initiate Phase 1b Clinical Trial in TNBC at Mayo Clinic in Fourth Quarter 2025FLORHAM PARK, N.J. and LONDON and CHARLOTTESVILLE, Va., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (“Cellectar”) (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, and Evestia Clinical (“Evestia”), a leading independent global specialist Contract Research Organization (CRO), have entered into an ag
About this update from Cellectar Biosciences, Inc.
[{"type":"image","alt":"Cellectar Biosciences, Inc.","displaySize":"","headline":null,"caption":"Cellectar Biosciences, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":296,"height":300,"url":"https://media.zenfs.com/en/globenewswire.com/7baccc0d962891d85da2697559b3ccb0"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/qCQXkIySESVHpCuJXj8EOw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTQyNjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/7baccc0d962891d85da2697559b3ccb0","width":296,"height":300}},"lazy":false},{"type":"text","content":"Intends to Initiate Phase 1b Clinical Trial in TNBC at Mayo Clinic in Fourth Quarter 2025","length":89,"tagName":"p"},{"type":"text","content":"FLORHAM PARK, N.J. and LONDON and CHARLOTTESVILLE, Va., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (“Cellectar”) (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, and Evestia Clinical (“Evestia”), a leading independent global specialist Contract Research Organization (CRO), have entered into an agreement whereby Evestia will provide Cellectar with full CRO services for their upcoming Phase 1b study evaluating CLR 125 for the treatment of triple-negative breast cancer (TNBC). CLR 125 is an iodine-125 Auger-emitting drug candidate targeting solid tumors, such as triple negative breast, lung and colorectal cancers.","length":732,"tagName":"p"},{"type":"text","content":"The new contract will leverage Evestia Clinical’s newly expanded global capabilities and oncology expertise, enhanced by its recent merger with Atlantic Research Group (ARG). Evestia’s experience in oncology spans both adult and pediatric populations, with participation in more than 300 studies across a wide range of solid tumors and hematologic malignancies and collaboration with many reputable clinic sites, including the Mayo Clinic.","length":439,"tagName":"p"},{"type":"text","content":"“ARG has been a trusted CRO partner for years and we are pleased to continue to work with the expanded team at Evestia Clinical, confident that their combined expertise and tailored approach will be instrumental in contributing to the success of this important clinical trial,” said Jarrod Longcor, chief operating officer of Cellectar. “We have unwavering confidence in CLR 125, and initiation of...